BrainsWay Ltd. (BWAY)
$
9.98
-0.29 (-2.91%)
Key metrics
Financial statements
Free cash flow per share
0.1988
Market cap
159.2 Million
Price to sales ratio
4.1211
Debt to equity
0
Current ratio
4.5187
Income quality
6.1853
Average inventory
3.7 Million
ROE
0.0352
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
News
zacks.com
Brainsway (BWAY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
zacks.com
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Brainsway (BWAY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
globenewswire.com
Achieved r ecord quarterly s ales of $11. 5 million in Q 1 202 5 , an increase of 27% compared to Q 1 202 4
seekingalpha.com
BrainsWay Ltd. (NASDAQ:BWAY ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Hadar Levy - Chief Executive Officer Ido Marom - Chief Financial Officer Conference Call Participants Steven Lichtman - Oppenheimer Jeffrey S.
globenewswire.com
Achieved r ecord quarterly s ales of $11.4 million in Q4 2024 , an increase of 27% compared with Q4 2023
zacks.com
BrainsWay BWAY shares plunged 15.7% in the past four trading sessions, falling below the 50-day moving average, implying weakness in the stock. Meanwhile, BWAY is scheduled to release its fourth-quarter results on March 11.
zacks.com
If you are looking for stocks that are well positioned to maintain their recent uptrend, Brainsway (BWAY) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
zacks.com
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are SBFG, FCCO, SNEX, BYRN, BWAY.
zacks.com
Let us take a look at four top-ranked stocks, AVO, ACEL, BWAY and FRBA, with stellar net profit margins that can help create a winning portfolio.
zacks.com
Bridgewater Bancshares, Eastern Bankshares and BrainsWay have been selected as the breakout stocks for today.
See all news
